Sign in
Not yet recruitingPhase 2/3

Physiological Effects of Nebulized Salbutamol in Acute Respiratory Failure Patients on HFNC

Key facts

Who runs it
Università degli Studi di Ferrara
Where
Italy1 site in 1 countryChoose a country to see its sites
Trial code
Status
Not yet recruiting
Phase
Phase 2/3
People taking part
20 people, planned
Started
1 Mar 2025
Planned end
Jul 2026
Type of study
Interventional
Treatments tested
  • salbutamol 2.5 mg via vibrating mesh nebulizer (VMN)
Record updated
7 February 2025

Who can take part

Age
18 years to 90 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (2)Hide the full registry criteria

Who can take part

  • • Age > 18, < 90 years; Non-intubated critically ill patients with AHRF due to pneumonia (diagnosis is based on the presence of infiltrates on chest X-ray and the onset of clinical signs of infection less than 7 days earlier); PaO2/FiO2 ≤ 300 mmHg; Patients receiving oxygen therapy

Who cannot take part

  • • Age < 18 years; Hypercapnia (PaCO2 > 50 mmHg); Hemodynamic instability (Systolic blood pressure < 90 mmHg or Mean arterial pressure < 60 or high dose of vasoactive drugs); Tachycardia or tachyarrhythmia (HR > 130 b/min); Known allergy or intolerance to salbutamol; Patient has received inhaled therapy with short-acting beta 2 agonists < 8 hours before or with long-acting beta 2 agonists < 24 hours before; Acute exacerbation of COPD or bronchial asthma; Cardiogenic pulmonary edema; GCS ≤ 12; Contraindication for EIT (e.g. ICD); Pregnancy; Patient refuses to participate

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Acute respiratory failure or pneumonia

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is a prospective physiological interventional study that assess the feasibility and safety of administering salbutamol using a vibrating mesh nebulizer during HFNC in patients with acute hypoxemic respiratory failure (AHRF). We evaluate whether this method of salbutamol delivery can reduce inspiratory effort and improve global and regional lung ventilation in AHRF patients. To achieve this, the study will record and analyze the following: esophageal pressure (Pes) curves, global and regional tidal volumes, minute ventilation, and changes in global and regional lung ventilation assessed through Electrical Impedance Tomography (EIT).

The group in the trial

  • SalbutamolTreatment being tested

    All patients will received ventilatory support with HFNC by adjusting gas flows to 30 L/min with 100% relative humidity, heated to 37 C, adjusting FiO2 levels to maintain SpO2 between 92 and 96%. After 20 min, each patient remaining on ventilatory support with HFNC will receive administration of salbutamol 2.5 mg via the vibrating mesh nebulizer (VMN) (Aerogen Solo®, Aerogen Ltd., Galway, Ireland) positioned immediately downstream of the humidification chamber of the HFNC system, using the dedicated connector.

    Treatment: salbutamol 2.5 mg via vibrating mesh nebulizer (VMN)

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
The Physiological Effects of Nebulized Salbutamol in Patients With Acute Respiratory Failure During HFNC
Criteria questions
Built from NCT06815679, who can take part
Record updated
7 February 2025